Vaccine-induced thrombotic thrombocytopenia following coronavirus vaccine: A narrative review

This study aims to review the pathophysiology, diagnosis, and management of vaccine-induced thrombotic thrombocytopenia, to provide a concise and comprehensive update.PMID:34745596 | PMC:PMC8556865 | DOI:10.1016/j.amsu.2021.102988
Source: Annals of Medicine - Category: Internal Medicine Authors: Source Type: research

Related Links:

Abdellatif The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, is currently developing into a rapidly disseminating and an overwhelming worldwide pandemic. In severe COVID-19 cases, hypercoagulability and inflammation are two crucial complications responsible for poor prognosis and mortality. In addition, coagulation system activation and inflammation overlap and produce life-threatening complications, including coagulopathy and cytokine storm, which are associated with overproduction of cytokines and activation of the immune system; they might be a lead cause of organ damage. ...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
Malay Sarkar, Irappa V Madabhavi, Pham Nguyen Quy, Manjunath B GovindagoudarAnnals of Thoracic Medicine 2022 17(1):1-13 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus responsible for the pandemic coronavirus disease 19 (COVID-19). It has significant impact on human health and public safety along with negative social and economic consequences. Vaccination against SARS-CoV-2 is likely the most effective approach to sustainably control the global COVID-19 pandemic. Vaccination is highly effective in reducing the risk of severe COVID-19 disease. Mass-scale vac...
Source: Annals of Thoracic Medicine - Category: Respiratory Medicine Authors: Source Type: research
Currently, the world is coping with the COVID-19 pandemic with a few vaccines. So far, the European Medicine Agency has approved four of them. However, following widespread vaccination with the recombinant adenoviral vector-based Oxford-AstraZeneca vaccine, available only in the United Kingdom and Europe, many concerns have emerged, especially the report of several cases of the otherwise rare cerebral sinus vein thrombosis and splanchnic vein thrombosis. The onset of thrombosis particularly at these unusual sites, about 5--14 days after vaccination, along with thrombocytopenia and other specific blood test abnormalities,...
Source: Journal of Cardiovascular Medicine - Category: Cardiology Tags: Reviews Source Type: research
Since the first cases were discovered at the end of 2019, the ongoing coronavirus disease 2019 (COVID-19) pandemic has significantly changed the lives of people around the world. Vaccines to prevent infection from its causative organism, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were developed by the end of 2020 and have now become humanity's hope of regaining normalcy by acquiring protective immunity against COVID-19. However, as vaccines against COVID-19 have been distributed globally at an unprecedented rate, cases of serious adverse events post-vaccination have been accumulating.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
CONCLUSIONS: Vaccine-induced immune thrombotic thrombocytopenia is a serious complication of vaccination that is not feasible to anticipate or prevent. When the patient presents with sustained headache, neurologic symptoms/signs, abdominal pain, dyspnea, or limb pain/swelling beginning 5–30 days post vaccination, platelet count and d-dimer must be measured, and imaging for thrombosis performed. Confirmation of vaccine-induced immune thrombotic thrombocytopenia diagnosis should be ordered (platelet factor 4/polyanion enzyme-linked immunosorbent assay; platelet factor 4–enhanced platelet activation testing) a...
Source: Critical Care Medicine - Category: Emergency Medicine Tags: Online Review Article Source Type: research
NEW BRUNSWICK, N.J., December 16, 2021 – Johnson &Johnson remains confident in the overall positive benefit-risk profile of its COVID-19 vaccine. Studies have shown that the Johnson &Johnson COVID-19 vaccine generates strong antibody and cellular immune responses [i] and long-lasting immune memory[ii] and breadth of protection across variants. In addition, a growing body of evidence is revealing the strength of protection of our vaccine as a booster to either the Janssen COVID-19 vaccine or a different authorized or approved COVID-19 vaccine, both in terms of its efficacy and durability.[iii], [iv], [v], [vi]...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
ConclusionFurther studies are needed to better identify VITT’s pathophysiological mechanisms and genetic, demographic, or clinical predisposition of high-risk patients, to investigate the correlation of VITT with the different vaccine types, and to test the significance of the findings.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractSince the emergence of the coronavirus disease 2019 (COVID-19) pandemic, multiple but rare complications of this infection have been described, comprising cerebral venous sinus thrombosis (CVST) and immune thrombocytopenic purpura (ITP). Although these two complications have been reported as separate entities, to the best of our knowledge, their concurrent presentation has not been reported. In this case report, we present a middle-aged man with a history of COVID-19 infection who developed a sudden-onset severe occipital headache followed by right-sided blindness (right homonymous hemianopia). Upon his diagnostic ...
Source: Neurology and Therapy - Category: Neurology Source Type: research
Semin Thromb Hemost DOI: 10.1055/s-0041-1736168Despite the huge efforts globally underway for preventing or limiting the spread of severe acute respiratory coronavirus disease 2 (SARS-CoV-2), the coronavirus disease 2019 (COVID-19) pandemic outbreak appears still virtually unstoppable. As for many other infectious diseases, COVID-19 vaccination has now become crucial for limiting viral spread, especially for averting hospitalizations, need for intensive care, and fatal outcome. Nonetheless, as for other vaccines, COVID-19 vaccination is not completely free from side effects. Among the adverse events that have been reported...
Source: Seminars in Thrombosis and Hemostasis - Category: Hematology Authors: Tags: Review Article Source Type: research
Vaccination is an effective strategy to reduce the burden of the coronavirus disease 2019 (COVID-19) pandemic. A number of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved and proven highly effective, without a counterbalancing safety signal in randomized trials [1 –4].
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research
More News: Coronavirus | COVID-19 | Economy | Internal Medicine | Pandemics | Smokers | Study | Thrombocytopenia | Thrombosis | Vaccines